Abstract
To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of irinotecan and raltitrexed given as sequential short infusions every 3 weeks, 33 patients with pretreated gastrointestinal adenocarcinoma (31 colorectal, 2 oesophagogastric) entered this open label dose-escalation study. For the first five dose levels patients received irinotecan 175–350 mg m–2 followed by raltitrexed 2.6 mg m–2. Level VI was irinotecan 350 mg m–2 plus raltitrexed 3.0 mg m–2, level VII was irinotecan 400 mg m–2 plus raltitrexed 2.6 mg m–2; 261 courses were administered. Only one patient at dose levels I–V experienced DLT. At level VI, 5/12 patients experienced DLT: one had grade 3 diarrhoea and lethargy, one had grade 4 diarrhoea and one had lethargy alone. Two others had lethargy caused by disease progression. There was no first-cycle neutropenia. At level VII, 3/6 patients experienced dose-limiting lethargy, one also had grade 3 diarrhoea. Dose intensity fell from over 90% for both drugs at level VI to 83% for irinotecan and 66% for raltitrexed at level VII. Lethargy was therefore the DLT, and level VII the MTD. Pharmacokinetic data showed no measurable drug interaction; 6/30 patients (20%) had objective responses. This combination is active with manageable toxicity. Recommended doses for further evaluation are irinotecan 350 mg m–2 and raltitrexed 3.0 mg m–2. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P and Gandia D (1994) Irinotecan (CPT-11) high dose escalation using intensive high-dose loperamide to control diarrhoea. J Natl Cancer Inst 86: 446–449
Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A and Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210–221
Aherne GW, Ward E, Lawrence N, Dobinson D, Clarke SJ, Musgrove H, Sutcliffe F, Stephens T and Jackman AL (1998) Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamable quinazoline thymidylate synthase inhibitor in preclinical models. Br J Cancer 77: 221–226
Armand JP (1996) CPT-11: clinical experience in phase I studies. Semin Oncol 23: 27–33
Aschele C, Baldo C, Sobrero A, Debernardis D, Bornmann WG and Bertino JR (1998) Schedule dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clinical Cancer Research 4: 1323–1330
Beale P, Judson I, Hanwell J, Berry C, Aherne W, Hickish T, Martin P and Walker M (1998) Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Canc Chemother Pharmacol 42: 71–76
Chabot GG, Abigerges D, Cartimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Herait P, Armand JP and Bugat R (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6: 141–151
Clarke SJ, Hanwel J, De Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealy GT and Judson IR (1996) Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumours. J Clin Oncol 14: 1495–1503
Cunningham D, Zalcberg JR, Rath U, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D and Perez Manga G (1996) Final results of a randomised trial comparing ‘Tomudex’ (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7: 961–965
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P A randomised phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients with metastatic colorectal cancer (MCRC) as frontline therapy. Lancet 355: 1041–1047
Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potemsil M (1989) DNA topoisomerase l-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046–1048
Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG and Allegra CJ (2000) A phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. Clinical Cancer Research 5: 2381–2391
Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR (1991) ICI DI694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579–5586
Judson I, Maughan TS, Beale P, Primrose J, Hoskin P, Hanwell J, Berry C, Walker M and Sutcliffe F (1998) Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex, ZD1694). Br J Cancer 78(9): 1188–1193
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Murad AM, Santiago FF, Petroianu A, Petroianu A, Rocha PRS, Rodrigues MAG and Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72: 37–41
Nordic Gastrointestinal Tumor Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colon cancer: a randomized trial. J Clin Oncol 10: 904–911
O’Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW and Potemsil M (2000) Antiangiogenic effects of camptothecin analogs 9-amino-10(S)-camptothecin, topotecan and CPT-11 studied in the mouse cornea model. Clinical Cancer Research 5(1): 181–187
Raymond E, Vernillet L, Boige V, Hua A, Ducreux M, Faivre S, Jacques C, Gatineau D, Mignard D, Vergniol JC, Rixe O and Armand JP (2000) Phase I and Pharmacokinetic (PK) Study of Irinotecan (CPT-11) in Cancer Patients (pts) with Hepatic Dysfunction. Proc Am Soc Clin Oncol 18: 165a (abstract 634)
Ross PJ, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R and Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995–1001
Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M and Extra JM (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapynaïve patients and patients pretreated with fluorouracil based chemotherapy. J Clin Oncol 15: 251–260
Saltz LB, Kanowitz J, Kemeny NE, Schaak L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M and Dietz A (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients wit advanced solid tumors. J Clin Oncol 14: 2959–2967
Saltz LB, Locker PK, Pirotta N, Elfring GL and Miller LL (2000) Weekly irinotecan (CPT-11), leucovorin (LV) and fluorouracil (FU) is superior to daily x5 LV/FU in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 18: 233a (abstract 898)
Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA, Degen D and Von Hoff D (1994) Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 5: 202–206
Webb A, Cunningham D, Howard Scarffe J, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O’Brien M, Iveson T, Watson M, Underhill C, Wardley A and Meehan M (1997) Randomised trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261–267
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ford, H., Cunningham, D., Ross, P. et al. Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma. Br J Cancer 83, 146–152 (2000). https://doi.org/10.1054/bjoc.2000.1192
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1192
Keywords
This article is cited by
-
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Clinical Pharmacokinetics (2018)
-
Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma
Journal of Gastrointestinal Cancer (2015)
-
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
British Journal of Cancer (2004)
-
Medical treatment of advanced colorectal carcinoma
Clinical and Translational Oncology (2004)
-
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
British Journal of Cancer (2003)